US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). D

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku
Links
https://bit.ly/3l2i53P

Systematic review of MRI confirm degenerative meniscus tears compared arthroscopic meniscectomy (APM) vs non-surgical o

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Systematic review of MRI confirm degenerative meniscus tears compared arthroscopic meniscectomy (APM) vs non-surgical or sham Rx. Results: 10 trials, 605 patients showed at 24 mos F/U, no advantage in Function or QOL favoring APM - rec conservative Rx https://t.co/4CwicQ9Jac https://t.co/3IrSRkNgqp
Links
https://bit.ly/3JweQeW

Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, accord

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, according to a new study. A combination of proteins and antioxidants doubles the anti-inflammatory properties. https://t.co/As8lhxnifp https://t.co/eZKD8Y6oTx
Links
https://bit.ly/3jq38bh

Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% be

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/iGtJUa991N https://t.co/PTPTUskUaa
Links
https://bit.ly/3x3BsfH
31 January 2023
Herpes Zoster with JAK Inhibitors
JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
31 January 2023
Bad Stress

“Bad is stronger than good.” 

Wait, bad is bad, right?

No good should come of bad. But if you reconsider bad, it could be a challenge, and not a pothole. Success and great opportunity are often the rebound to adversity (bad) or failure. Yet, for most, bad drives the story we tell ourselves; a deflating spin of negativism that is sticky or inescapable.

For you, bad happenings this week could be the rebound motivator for tomorrow’s solutions. If your past informs your future, then your “bad” can certainly improve your future.

1st there was combined Rheum-Derm or Rheum-Pulm clinics. Medscape reports new Rheum-Cardiology clinics at Cleveland Clin

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
1st there was combined Rheum-Derm or Rheum-Pulm clinics. Medscape reports new Rheum-Cardiology clinics at Cleveland Clinic, NYU, Brigham, Stanford. Useful in research, managing Rheum pts a) at hi CV risk, B) having procedures/surgery, c) risk reduction https://t.co/9AqujArSMT https://t.co/3ZVORt9gK9
Links
https://wb.md/3Dw6HUa

FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refr

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/gDHbcDpNnT https://t.co/oL0nldQ1fN
Links
https://bit.ly/3kWpm50

Last day for early bird pricing! https://t.co/KwQnDC4Pdz RheumNow Live is a 1.5-day long meeting that offers pre-lear

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Last day for early bird pricing! https://t.co/KwQnDC4Pdz RheumNow Live is a 1.5-day long meeting that offers pre-learning modules, shorter, concise lectures with clinical context and audience input, more discussion time, and sessions that are relaxed and comprehensive. https://t.co/W4mqIyhgRS
Links
https://bit.ly/3jlreUo
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×